Open AccessPegylated Long-Acting Human Growth Hormone Possesses a Promising Once-Weekly Treatment Profile, and Multiple Dosing Is Well Tolerated in Adult Patients with Growth Hormone Deficiency
Author(s) -
Esben Søndergaard,
Marianne Klose,
Mette Hansen,
Birgit Sehested Hansen,
Marianne Andersen,
Ulla FeldtRasmussen,
Torben Laursen,
Michael Højby Rasmussen,
Jens Sandahl Christiansen
Publication year - 2010
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2010-1931
Subject(s) - tolerability , pharmacokinetics , dosing , medicine , pharmacodynamics , placebo , growth hormone deficiency , endocrinology , somatropin , glycated hemoglobin , lean body mass , pharmacology , adverse effect , growth hormone , hormone , diabetes mellitus , type 2 diabetes , body weight , alternative medicine , pathology
Recombinant human GH (rhGH) replacement therapy in children and adults currently requires daily sc injections for several years or lifelong, which may be both inconvenient and distressing for patients. NNC126-0083 is a pegylated rhGH developed for once-weekly administration.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom